Abstract
The optimal post-remission treatment for elderly patients with acute myeloid leukemia (AML) is presently unknown. Recent studies have reported the feasibility of autologous peripheral blood stem cell transplantation (PBSCT) in this population. We evaluate the outcome of this post-remission approach after complete remission (CR) and consolidation in elderly patients included in the EORTC-GIMEMA AML-13 trial.
Lingua originale | English |
---|---|
pagine (da-a) | 389-396 |
Numero di pagine | 8 |
Rivista | Haematologica |
Volume | 92 |
Stato di pubblicazione | Pubblicato - 2007 |
Pubblicato esternamente | Sì |
Keywords
- Administration, Oral
- Aged
- Aged, 80 and over
- Amsacrine
- Antineoplastic Combined Chemotherapy Protocols
- Carmustine
- Combined Modality Therapy
- Cytarabine
- Disease-Free Survival
- Etoposide
- Feasibility Studies
- Female
- Graft Survival
- Granulocyte Colony-Stimulating Factor
- Hematopoietic Stem Cell Transplantation
- Humans
- Idarubicin
- Infusions, Intravenous
- Injections, Subcutaneous
- Kaplan-Meier Estimate
- Leukemia, Myeloid
- Male
- Middle Aged
- Peripheral Blood Stem Cell Transplantation
- Prospective Studies
- Recombinant Proteins
- Survival Analysis
- Transplantation Conditioning
- Transplantation, Autologous
- Treatment Outcome